|
1
|
Jiang Y, Ludwig J and Janku F: Targeted
therapies for advanced Ewing sarcoma family of tumors. Cancer Treat
Rev. 41:391–400. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
de Alava E and Gerald WL: Molecular
biology of the Ewing's sarcoma/primitive neuroectodermal tumor
family. J Clin Oncol. 18:204–213. 2000.PubMed/NCBI
|
|
3
|
Cidre-Aranaz F and Alonso J: EWS/FLI1
target genes and therapeutic opportunities in Ewing sarcoma. Front
Oncol. 5:1622015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Toomey EC, Schiffman JD and Lessnick SL:
Recent advances in the molecular pathogenesis of Ewing's sarcoma.
Oncogene. 29:4504–4516. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Smith R, Owen LA, Trem DJ, Wong JS,
Whangbo JS, Golub TR and Lessnick SL: Expression profiling of
EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's
sarcoma. Cancer Cell. 9:405–416. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liebner DA: The indications and efficacy
of conventional chemotherapy in primary and recurrent sarcoma. J
Surg Oncol. 111:622–631. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Paulussen M, Craft AW, Lewis I, Hackshaw
A, Douglas C, Dunst J, Schuck A, Winkelmann W, Köhler G, Poremba C,
et al; European Intergroup Cooperative Ewing's Sarcoma Study-92.
Results of the EICESS-92 Study: Two randomized trials of Ewing's
sarcoma treatment - cyclophosphamide compared with ifosfamide in
standard-risk patients and assessment of benefit of etoposide added
to standard treatment in high-risk patients. J Clin Oncol.
26:4385–4393. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
May WA, Grigoryan RS, Keshelava N, Cabral
DJ, Christensen LL, Jenabi J, Ji L, Triche TJ, Lawlor ER and
Reynolds CP: Characterization and drug resistance patterns of
Ewing's sarcoma family tumor cell lines. PLoS One. 8:e800602013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Oda Y, Dockhorn-Dworniczak B, Jürgens H
and Roessner A: Expression of multidrug resistance-associated
protein gene in Ewing's sarcoma and malignant peripheral
neuroectodermal tumor of bone. J Cancer Res Clin Oncol.
123:237–239. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gottesman MM: Mechanisms of cancer drug
resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Beauchamp E, Bulut G, Abaan O, Chen K,
Merchant A, Matsui W, Endo Y, Rubin JS, Toretsky J and Uren A: GLI1
is a direct transcriptional target of EWS-FLI1 oncoprotein. J Biol
Chem. 284:9074–9082. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Joo J, Christensen L, Warner K, States L,
Kang HG, Vo K, Lawlor ER and May WA: GLI1 is a central mediator of
EWS/FLI1 signaling in Ewing tumors. PLoS One. 4:e76082009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zwerner JP, Joo J, Warner KL, Christensen
L, Hu-Lieskovan S, Triche TJ and May WA: The EWS/FLI1 oncogenic
transcription factor deregulates GLI1. Oncogene. 27:3282–3291.
2008. View Article : Google Scholar
|
|
14
|
Boehme KA, Zaborski JJ, Riester R,
Schweiss SK, Hopp U, Traub F, Kluba T, Handgretinger R and
Schleicher SB: Targeting hedgehog signalling by arsenic trioxide
reduces cell growth and induces apoptosis in rhabdomyosarcoma. Int
J Oncol. 48:801–812. 2016.
|
|
15
|
Beauchamp EM, Ringer L, Bulut G, Sajwan
KP, Hall MD, Lee YC, Peaceman D, Ozdemirli M, Rodriguez O,
Macdonald TJ, et al: Arsenic trioxide inhibits human cancer cell
growth and tumor development in mice by blocking Hedgehog/GLI
pathway. J Clin Invest. 121:148–160. 2011. View Article : Google Scholar :
|
|
16
|
Zhang S, Guo W, Ren TT, Lu XC, Tang GQ and
Zhao FL: Arsenic trioxide inhibits Ewing's sarcoma cell
invasiveness by targeting p38(MAPK) and c-Jun N-terminal kinase.
Anticancer Drugs. 23:108–118. 2012. View Article : Google Scholar
|
|
17
|
Matsumoto T, Tabata K and Suzuki T: The
GANT61, a GLI inhibitor, induces caspase-independent apoptosis of
SK-N-LO cells. Biol Pharm Bull. 37:633–641. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Battula VL, Treml S, Bareiss PM, Gieseke
F, Roelofs H, de Zwart P, Müller I, Schewe B, Skutella T, Fibbe WE,
et al: Isolation of functionally distinct mesenchymal stem cell
subsets using antibodies against CD56, CD271, and mesenchymal stem
cell antigen-1. Haematologica. 94:173–184. 2009. View Article : Google Scholar :
|
|
19
|
Laurendeau I, Ferrer M, Garrido D, D'Haene
N, Ciavarelli P, Basso A, Vidaud M, Bieche I, Salmon I and Szijan
I: Gene expression profiling of the hedgehog signaling pathway in
human meningiomas. Mol Med. 16:262–270. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kelleher FC, Cain JE, Healy JM, Watkins DN
and Thomas DM: Prevailing importance of the hedgehog signaling
pathway and the potential for treatment advancement in sarcoma.
Pharmacol Ther. 136:153–168. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Amakye D, Jagani Z and Dorsch M:
Unraveling the therapeutic potential of the Hedgehog pathway in
cancer. Nat Med. 19:1410–1422. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lin PP, Wang Y and Lozano G: Mesenchymal
stem cells and the origin of Ewing's sarcoma. Sarcoma.
2011:2764632011. View Article : Google Scholar
|
|
23
|
Sand LG, Szuhai K and Hogendoorn PC:
Sequencing overview of Ewing sarcoma: A journey across genomic,
epigenomic and transcriptomic landscapes. Int J Mol Sci.
16:16176–16215. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Aberger F and Ruiz I Altaba A:
Context-dependent signal integration by the GLI code: The oncogenic
load, pathways, modifiers and implications for cancer therapy.
Semin Cell Dev Biol. 33:93–104. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Watts JM and Tallman MS: Acute
promyelocytic leukemia: What is the new standard of care? Blood
Rev. 28:205–212. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Raju GP: Arsenic: A potentially useful
poison for Hedgehog-driven cancers. J Clin Invest. 121:14–16. 2011.
View Article : Google Scholar :
|
|
27
|
Kim J, Aftab BT, Tang JY, Kim D, Lee AH,
Rezaee M, Kim J, Chen B, King EM, Borodovsky A, et al: Itraconazole
and arsenic trioxide inhibit Hedgehog pathway activation and tumor
growth associated with acquired resistance to smoothened
antagonists. Cancer Cell. 23:23–34. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Au WY, Tam S, Fong BM and Kwong YL:
Determinants of cerebrospinal fluid arsenic concentration in
patients with acute promyelocytic leukemia on oral arsenic trioxide
therapy. Blood. 112:3587–3590. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mathieu J and Besançon F: Clinically
tolerable concentrations of arsenic trioxide induce p53-independent
cell death and repress NF-kappa B activation in Ewing sarcoma
cells. Int J Cancer. 119:1723–1727. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Emadi A and Gore SD: Arsenic trioxide - An
old drug rediscovered. Blood Rev. 24:191–199. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sordet O, Liao Z, Liu H, Antony S, Stevens
EV, Kohlhagen G, Fu H and Pommier Y: Topoisomerase I-DNA complexes
contribute to arsenic trioxide-induced apoptosis. J Biol Chem.
279:33968–33975. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tan B, Piwnica-Worms D and Ratner L:
Multidrug resistance transporters and modulation. Curr Opin Oncol.
12:450–458. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Melguizo C, Prados J, Rama AR, Ortiz R,
Álvarez PJ, Fernández JE and Aranega A: Multidrug resistance and
rhabdomyosarcoma (Review). Oncol Rep. 26:755–761. 2011.PubMed/NCBI
|
|
34
|
Santisteban M: ABC transporters as
molecular effectors of pancreatic oncogenic pathways: The
Hedgehog-GLI model. J Gastrointest Cancer. 41:153–158. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Leslie EM, Haimeur A and Waalkes MP:
Arsenic transport by the human multidrug resistance protein 1
(MRP1/ABCC1). Evidence that a tri-glutathione conjugate is
required. J Biol Chem. 279:32700–32708. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Feng T, Qiao G, Feng L, Qi W, Huang Y, Yao
Y and Shen Z: Stathmin is key in reversion of doxorubicin
resistance by arsenic trioxide in osteosarcoma cells. Mol Med Rep.
10:2985–2992. 2014.PubMed/NCBI
|
|
37
|
Guo W, Tang XD, Tang S and Yang Y:
Preliminary report of combination chemotherapy including Arsenic
trioxide for stage III osteosarcoma and Ewing sarcoma. Zhonghua Wai
Ke Za Zhi. 44:805–808. 2006.(In Chinese). PubMed/NCBI
|
|
38
|
Zhao YY, Yu L, Liu BL, He XJ and Zhang BY:
Downregulation of P-gp, Ras and p-ERK1/2 contributes to the arsenic
trioxide-induced reduction in drug resistance towards doxorubicin
in gastric cancer cell lines. Mol Med Rep. 12:7335–7343.
2015.PubMed/NCBI
|
